Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE

Protocol No
NEURO-TG-ENHANCE
Staff Member
Ahmed Obeidat
Phase
III
Summary

This project is being done to see how effective and tolerable ublituximab is when given to people who have never received treatment for their relapsing multiple sclerosis or who have been receiving different disease modifying therapy (DMT) for relapsing multiple sclerosis.
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Multiple Sclerosis, Brain, Spinal Cord, and Nervous System
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05877963